Provider Perspectives on Patient-provider Communication for Adjuvant Endocrine Therapy Symptom Management
Overview
Oncology
Authors
Affiliations
Purpose: Providers' communication skills play a key role in encouraging breast cancer survivors to report symptoms and adhere to long-term treatments such as adjuvant endocrine therapy (AET). The purpose of this study was to examine provider perspectives on patient-provider communication regarding AET symptom management and to explore whether provider perspectives vary across the multi-disciplinary team of providers involved in survivorship care.
Methods: We conducted three one-hour focus groups with a multi-disciplinary group of health care providers including oncology specialists, primary care physicians, and non-physician providers experienced in caring for breast cancer survivors undergoing AET (n = 13). Themes were organized using Epstein and Street's (2007) Framework for Patient-Centered Communication in Cancer Care.
Results: The findings of this study suggest providers' communication behaviors including managing survivors' uncertainty, responding to survivors' emotions, exchanging information, and enabling self-management influences the quality of patient-provider communication about AET symptoms. Additionally, lack of systematic symptom assessment tools for AET requires providers to use discretion in determining which symptoms to discuss with survivors resulting in approaches that vary based on providers' discipline.
Conclusion: There may be AET-specific provider communication skills and behaviors that promote effective patient-provider communication but additional research is needed to identify practices and policies that encourage these skills and behaviors among the many providers involved in survivorship care. Efforts are also needed to coordinate AET symptom assessment across providers, clarify providers' roles in symptom assessment, and determine best practices for AET symptom communication.
Wang L, Wei T, Liu J, Peng S, Chen J, Hu M BMJ Open. 2023; 13(12):e073915.
PMID: 38149416 PMC: 10711849. DOI: 10.1136/bmjopen-2023-073915.
Anderson J, Paladino A, Blue R, Dangerfield 2nd D, Eggly S, Martin M J Cancer Surviv. 2023; .
PMID: 38114711 PMC: 11216545. DOI: 10.1007/s11764-023-01511-0.
Anderson J, Krukowski R, Paladino A, Graff J, Schwartzberg L, Curry A J Hosp Manag Health Policy. 2021; 5.
PMID: 34308256 PMC: 8302021. DOI: 10.21037/jhmhp-20-103.
Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer.
Lambert L, Balneaves L, Howard A, Chia S, Gotay C Curr Oncol. 2021; 28(2):1472-1482.
PMID: 33918560 PMC: 8167827. DOI: 10.3390/curroncol28020139.
Sheppard V, Sutton A, Hurtado-de-Mendoza A, He J, Dahman B, Edmonds M Cancer Epidemiol Biomarkers Prev. 2021; 30(4):699-709.
PMID: 33514603 PMC: 8330157. DOI: 10.1158/1055-9965.EPI-20-0604.